首页 文献索引 SCI期刊 AI助手
首页 正文

Randomized Controlled Trial International journal of cardiology. 2021 Oct 1:340:96-104. doi: 10.1016/j.ijcard.2021.08.031 Q23.22025

Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry

关于心血管结局的普遍性REDUCE-IT试验以及潜在接受依洛尤单抗治疗的患者的高甘油三酯血症相关性：来自减少动脉栓塞以保持健康（REACH）登记处的一项分析 翻译改进

Fabien Picard  1, Deepak L Bhatt  2, Grégory Ducrocq  3, E Magnus Ohman  4, Shinya Goto  5, Kim A Eagle  6, Peter W F Wilson  7, Sidney C Smith Jr  8, Yedid Elbez  9, Philippe Gabriel Steg  10

作者单位 +展开

作者单位

  • 1 FACT (French Alliance for Cardiovascular Trials), Paris, France; Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • 2 Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
  • 3 FACT (French Alliance for Cardiovascular Trials), Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, and INSERM U1148, Paris, France; Université de Paris, Paris, France.
  • 4 Duke University Medical Center, Durham, NC, USA.
  • 5 Department of Medicine, Tokai University School of Medicine, Isehara, Japan.
  • 6 University of Michigan Health System, Ann Arbor, MI, USA.
  • 7 Atlanta VA Medical Center and Emory Cardiovascular Research Institute, GA, USA.
  • 8 Heart and Vascular Center, University of North Carolina at Chapel Hill, NC, USA.
  • 9 FACT (French Alliance for Cardiovascular Trials), Paris, France.
  • 10 FACT (French Alliance for Cardiovascular Trials), Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, and INSERM U1148, Paris, France; Université de Paris, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom. Electronic address: gabriel.steg@aphp.fr.

    • DOI: 10.1016/j.ijcard.2021.08.031 PMID: 34450192

    摘要 Ai翻译

    Background: The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) trial demonstrated that high-dose icosapent-ethyl reduced the risk of ischemic events in statin-treated patients with elevated triglycerides (TG) and either atherosclerotic cardiovascular disease (ASCVD) or diabetes plus at least one risk factor.

    Methods and results: Using data from REACH (Reduction of Atherothrombosis for Continued Health), a large international registry of outpatients with or at risk of ASCVD, we evaluated the proportion of patients potentially eligible for enrolment in REDUCE-IT and compared their outcomes to those excluded because of low TG. Among 62,464 patients with either ASCVD or diabetes enrolled in the REACH Registry, 1036/8418 (12.3%) patients in primary prevention and 6049/54046 (11.2%) patients in secondary prevention (11.3% overall) would have been eligible for inclusion in REDUCE-IT. Compared with patients excluded for low TG level, adjusted risk of the primary composite outcome of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, unstable angina, or coronary revascularization was higher in the REDUCE-IT eligible group (HR:1.06, 95%CI:1.00-1.13, p = 0.04). In addition, unstable angina, non-fatal MI, percutaneous coronary intervention and coronary artery bypass grafting were also more frequent in the REDUCE-IT eligible group (HR:1.17, 95%CI:1.07-1.27, p < 0.001; HR:1.25, 95%CI:1.07-1.45, p < 0.001; HR:1.42, 95%CI:1.27-1.57, p < 0.001; HR:1.43, 95%CI:1.19-1.71, p < 0.001, respectively), whereas the adjusted risk of non-fatal stroke was lower (HR:0.64, 95%CI:0.54-0.75, p < 0.001).

    Conclusion: In this large international registry of patients with or at high-risk of ASCVD, 11.3% met the REDUCE-IT trial selection criteria. REDUCE-IT eligible patients were found to be at higher risk of cardiac atherothrombotic events, but at lower risk of stroke than trial-ineligible patients with lower TG.

    Keywords: Atherosclerosis; Cardiovascular events; Dyslipidemia; Hypertriglyceridemia; Icosapent ethyl; Triglyceride.

    Keywords：cardiovascular outcomes; hypertriglyceridemia; icosapent ethyltherapy; REDUCE-IT trial

    关键词：心血管结局; 高甘油三酯血症; 依库比特乙醇治疗; REDUCE-IT试验

    Copyright © International journal of cardiology. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：International journal of cardiology

    缩写：INT J CARDIOL

    ISSN：0167-5273

    e-ISSN：1874-1754

    IF/分区：3.2/Q2

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry